OSCR | Ticker Profile - Titan Protect

OSCR

Oscar Health, Inc.

Healthcare · Healthcare Plans · NYQ

$24.51

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

15.72

Based on estimated future earnings — lower means cheaper

Rev Growth

+52.6%

Year-over-year revenue change

Profit Margin

-0.3%

How much profit the company keeps from each dollar of revenue

ROE

-2.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$21.00

-14% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 10 analysts covering this stock

About Oscar Health, Inc.

Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

https://www.hioscar.com

Country: United States Employees: 2,305 Industry: Healthcare Plans

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.439

Positive but modest risk-adjusted returns

Kelly Fraction

0.0319

Modest edge detected — smaller position warranted

Calmar Ratio

0.098

Drawdown risk outweighs the returns — higher risk profile

Annual Return

5.2%

Historical annualised return based on price data

Max Drawdown

-53.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

106

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.34

Significantly more volatile than the market

52W High

$25.58

4% below the year high

52W Low

$10.69

129% above the year low

Avg Volume

7,250,659

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.5%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.54

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

28.93

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.09

Adequate but worth monitoring

Quick Ratio

1.07

Like current ratio but excludes inventory — stricter test

Gross Margin

17.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

15.2%

Profit from core operations before interest and tax

Free Cash Flow

$1.6B

Positive — the business generates more cash than it spends

Revenue (TTM)

$13.3B

Total revenue over the last 12 months

Net Income

$-39,426,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$21.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go